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ABSTRACT.  
Gastrointestinal (GI) models that mimic physiological conditions in vitro are important tools for 
developing and optimizing biopharmaceutical formulations. Oral administration of live attenuated 
bacterial vaccines (LBV) can safely and effectively promote mucosal immunity but new formulations 
are required that provide controlled release of optimal numbers of viable bacterial cells, which must 
survive gastrointestinal transit overcoming various antimicrobial barriers. Here, we use a gastro-small 
intestine gut model of human GI conditions to study the survival and release kinetics of two oral LBV 
formulations: the licensed typhoid fever vaccine Vivotif comprising enteric coated capsules; and an 
experimental formulation of the model vaccine Salmonella Typhimurium SL3261 dried directly onto 
cast enteric polymer films and laminated to form a polymer film laminate (PFL). Neither formulation 
released significant numbers of viable cells when tested in the complete gastro-small intestine model. 
The poor performance in delivering viable cells could be attributed to a combination of acid and bile 
toxicity plus incomplete release of cells for Vivotif capsules, and to bile toxicity alone for PFL. To 
achieve effective protection from intestinal bile in addition to effective acid resistance, bile adsorbent 
resins were incorporated into the PFL to produce a new formulation, termed BR-PFL. Efficient and 
complete release of 4.4x10
7
 live cells per dose was achieved from BR-PFL at distal intestinal pH, with 
release kinetics controlled by the composition of the enteric polymer film, and no loss in viability 
observed in any stage of the GI model. Use of this in vitro GI model thereby allowed rational design of 
an oral LBV formulation to maximize viable cell release. 
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ABBREVIATIONS 
LBV, live bacterial vaccine; GI, gastro-intestinal; SIF, USP simulated intestinal fluid (pH 7.0); SGF, 
USP simulated gastric fluid (pH 2.0); BioSGF, complete simulated gastric fluid; BioSIF, complete 
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simulated intestinal fluid; CFU, colony forming unit; PFL, polymer film laminate; BR-PFL, bile resin 
polymer film laminate. 
 
Introduction 
Live bacterial cells are administered orally as attenuated vaccines [1], for in situ production of 
biopharmaceuticals [2], or as probiotics to improve gastrointestinal (GI) health [3]. Attenuated live 
bacterial vaccines (LBV) administered orally (e.g. Vivotif, CholeraGarde), closely mimic natural 
infection and promote potent, long-lasting protective immunity [1]. The small intestine mucosa, 
particularly the Peyer’s patches found in the ileum, is typically the target site for oral LBV. Although 
many formulations have been developed for oral delivery of therapeutic live bacteria ranging from 
exotic functional foods to yoghurt [4], solid dosage forms such as capsules or tablets containing dried 
live bacteria offer the most control of both dose and site of delivery whilst drying is essential to achieve 
stability and shelf life [5]. However, even in late stage clinical trials LBV are still being administered in 
bicarbonate buffer suspension reconstituted from lyophilized stocks (e.g. attenuated cholera strains 
Peru-15 [6] and CVD 103-HgR [7]) – a formulation that did not gain large scale adoption for Ty21a in 
spite of the greater immunogenicity of buffered liquid administration over capsules in clinical trials [8, 
9]. The poor palatability of bicarbonate buffers has led to the suggestion of alternate liquid 
formulations such as protein shakes [10] which provide effective protection of attenuated vaccine cells 
from gastric acid. 
Like other biopharmaceuticals, LBV present unique formulation challenges not only during 
manufacture but also after administration, and dried bacterial cells must survive many antimicrobial 
defenses during GI transit including gastric acid, antimicrobial, gastric and pancreatic enzymes, and 
bile surfactants. Although non-viable bacterial cells can promote immunity, viable cells are 
significantly more immunogenic [11]. These challenges are exacerbated by an elevated sensitivity to 
acid and bile when dried [12-14]. Acid-labile conventional pharmaceuticals are protected from gastric 
acid by encapsulation using gastro-resistant coatings such as acid-insoluble enteric polymers [15-17], 
and Vivotif is formulated in a capsule coated with hydroxypropymethylcellulose- phthalate. In contrast 
live bacterial vaccines in recent clinical trials utilize an unconventional oral delivery form, with 
lyophilized cells resuspended in a bicarbonate buffer in an effort to neutralize gastric acid following 
oral administration (e.g.  [6]). Delivery to the intestine using enteric coatings releases tablet or capsule 
content to intestinal microbicides including bile. Although the main function of bile acids is to 
solubilise dietary lipids, many microbes are intolerant to detergents and bile represents a major 
microbicidal barrier to the survival of bacteria in the gut. Drying even highly bile adapted enteric 
organisms such as Salmonella bacteria increases susceptibility to bile, raising the possibility that, but 
dry cells released from enteric coated formulations may then be rapidly killed by bile following 
intestinal release, dramatically reducing dose of viable cells. This temporary bile sensitivity of dried 
cells is rapidly reversed after rehydration and bile adsorbing resins can be added to oral formulations to 
protect dried cells from bile toxicity [12-14]. 
Understanding the fate of food and drugs after ingestion is both vital to achieve efficient 
delivery and uptake of pharmaceuticals and to understand the impact of diet on gut health, and in vitro 
modelling remains a critical tool for study of food and oral formulations in the GI tract. In vivo studies 
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are complex and expensive and although critical to understand vaccine efficacy, have not been used to 
assess the delivery of live bacterial vaccine cells; instead, preclinical studies focus on immunogenicity 
as a downstream consequence of administration of formulated cells. In some studies fecal shedding can 
be monitored as an indirect indicator of GI bacterial load but immune responses can be generated 
without fecal shedding proving this is a poor indicator of live cell delivery. Small animal models 
cannot be used to test human dosage forms as capsules and tablets are too large for oral administration, 
and there are no published reports of the release kinetics and location or number of viable cells released 
into the GI tract of large monogastric mammals from solid oral formulations of therapeutic live cells. 
As a result we know very little about the fate of live therapeutic cells administered orally, or the 
influence of cell viability and release location on downstream immunogenicity, and so carefully 
designed in vitro studies remain vital.  
Conventional dissolution testing utilizes very simple simulated GI fluids, typically a simple 
acidic simulated gastric fluid (SGF; often 0.1M HCl, pH ~ 2.0) followed by a simple phosphate buffer 
for simulated intestinal fluid (SIF; typically pH 6.8) to simulate intestinal transit, with some minor 
variations such as the pH or the addition of enzymes [18]. Although carefully defined simple 
dissolution testing protocols are adequate for testing small molecule drugs and essential for 
manufacturing quality control, these conditions poorly reflect the dynamic and complex physiological 
conditions encountered during GI transit in vivo. Simple SGF and SIF are particularly inappropriate for 
complex biological therapeutics such as live therapeutic bacteria since they lack antimicrobial 
components such as bile acids. Several validated gastrointestinal models have been developed [19] 
such as the three-stage compound continuous culture system that simulates the nutritional and 
environmental conditions in the human large intestine [20]; TIM, a multi-compartmental, dynamic 
computer-controlled model that simulates the GI tract [21]; and the simulator of the human microbial 
ecosystem (SHIME) which operates in sequential batch mode and simulates the entire human 
gastrointestinal system [22]. Here, we adapted an established gut model designed and validated to 
reproduce the spatial, temporal, nutritional, and physicochemical characteristics of the microbiota in 
the human colon [23] to the study of oral formulations of live bacterial vaccines. This three-stage 
continuous culture system comprises of three glass fermenters simulating the ascending, transverse, and 
distal colon, and contains a complete microbiota from a fecal inoculum.  
In this study, upstream gastric and small intestinal stages were added to this model to study 
viability and release of LBV from oral formulations through simulated GI transit. We evaluated the fate 
of LBV for both an established licensed oral vaccine formulation in a enteric coated capsules (Vivotif), 
and a novel polymer film laminate formulation developed recently by our laboratory [17]. These 
formulations were previously tested in simple SGF and SGF but the effect of complete simulated 
gastrointestinal fluids that mimic physiological conditions has not been reported. We found that dried 
Salmonella typhi strain Ty21a cells in the enteric coated Vivotif capsules were sensitive to both gastric 
acid and bile, suggesting that major losses in viable cell numbers are likely to be released in vivo from 
this widely used vaccine formulation. Likewise, although our novel enteric polymer film laminate 
(PFL) formulation was effective at protecting live bacteria of a model vaccine strain of Salmonella 
typhimurium from gastric acid, dried cells in this formulation remained highly susceptible to bile. We 
therefore incorporated bile sequestrants into the polymer films to produce a bile resistant polymer film 
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laminate (BR-PFL) formulation, which delivered maximal viable cells to the simulated distal intestinal 
site. 
 
Materials and methods 
 
Materials. Eudragit L100 55 (Eudragit L, methacrylic acid-ethyl acrylate copolymer 1:1), was 
provided from Evonik, Germany. Cholestyramine, triethyl citrate, sodium chloride, potassium 
phosphate buffer, pancreatin, pepsin, LB broth and LB agar were purchased from Sigma Aldrich 
(Gillingham, UK). Peptone and bile salts were from Oxoid (Basingstoke, UK). The oral typhoid fever 
vaccine Vivotif consisting of Salmonella Typhi strain Ty21a formulated in a capsule coated with 
hydroxypropymethylcellulose-phthalate, was from Crucell (Netherlands). The model live bacterial 
vaccine strain was Salmonella enterica serovar Typhimurium strain SL3261. 
In vitro gastro-small intestine model system. A semi-continuous gastro-small intestine model system 
was constructed (Fig. 1) consisting of four (V1, V2, V3 and V4) jacketed glass vessels (Soham 
scientific, UK), with operating volumes of 50, 100, 100 and 100 mL representing the stomach, 
duodenum, jejunum and ileum, respectively. Each vessel was completely sealed and had a cover 
designed to accommodate a sample glass holder (design to keep PFL form in place without affecting 
dissolution), pH electrode, temperature probe, and entry parts for N2, 0.5 M HCl, 0.5 M NaOH, and 
digesta if necessary, and contents continuously mixed by magnetic stirrer bar. The temperature was 
maintained by circulating water at 37 ºC through the jacketed vessels.  pH controller pumps (Fermac 
260; Electrolab, Tewkesbury, United Kingdom) were used to automatically control the pH of the 
simulated fluid in vessels V2, V3 and V4 to pH 5.5, 6.5 and 7.2, respectively. An anaerobic 
environment was maintained by sparing all vessels with O2-free N2 (15mL/min). 
 
FIGURE 1. A gastro small intestine model to study live bacterial vaccine delivery from oral formulations in vitro. 
Schematic diagram of the semi-continuous four stage in vitro gastro-small intestine model used in this study. The system 
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consists of four sequential vessels, V1 (50 mL, pH 1.8), V2 (100 mL pH 5.5), V3 (100 mL pH 6.5) and V4 (100 mL pH 
7.2), representing the stomach, duodenum, jejunum and ileum respectively. In each vessel temperature (37 °C) and pH were 
automatically controlled, contents were magnetically stirred and maintained under anaerobic conditions. A single dose of 
each vaccine formulation was submerged sequentially in the four stages, with transit times in each compartment of 2 hours 
in V1, 5 min in V2 , 25 min in V3  and 2.5 hours in V4. Samples were taken periodically and viable cell numbers counted 
by plating in replicate 
 
Simulated gastro-intestinal fluids. Pharmacopeia standard simple simulated gastro-intestinal fluids 
(USP26 - SGF or SIF) and complex simulated human gastro-intestinal fluids (BioSGF or BioSIF) had 
the following composition. SGF was 0.1 M HCl at pH 2.0. SIF was phosphate buffer at 0.68 % w/v 
potassium dihydrogen phosphate at pH 6.8 plus 1 % peptone (adjusted with 0.2 M NaOH or 0.2 M 
HCl). BioSGF was 0.2 % w/v NaCl, 0.03 % w/v bile salts and 0.3 % w/v pepsin, adjusted with 1 M 
HCl to pH 1.8. BioSIF was 0.4 % w/v NaCl, 1.1 % w/v bile salts, 1 % w/v pancreatin, 0.4% w/v 
phosphate buffer KH2PO4 and 1 % peptone adjusted with 0.5 M HCl or 0.5 M NaOH to pH 5.5 
(duodenum), pH 6.5 (jejunum) and pH 7.2 (ileum), respectively. All solutions and growth media were 
sterilized by autoclaving except enzyme/bile solutions that were sterile filtered. 
Preparation of polymer film laminate formulations (PFL) and Bile Resistant PFL. Polymer 
films were cast as described [17] from solutions of Eudragit L100 55 (12.5 % w/v) in ethanol with 25 
% w/w triethyl citrate plasticizer added based on the polymer mass. Where indicated the bile adsorbant 
resin cholestyramine (10 % w/v) was added to Eudragit L100 55 7.5 % w/v. Polymer solutions were 
cast in 90 mm diameter Petri dishes with the volumes adjusted (5-15 mL) to achieve a dry film 
thickness ranging from 100 µm to 200 µm. PFL - A was as previously described [17]. Novel bile 
resistant PFL (BR-PFL) were prepared as follows: BR-PFL B - 1 layer of Eudragit and cholestyramine; 
BR-PFL C 2 outer layer Eudragit alone, inner layer Eudragit + cholestyramine; BR-PFL D outer layer 
Eudragit alone, middle layer Eudragit + cholestyramine,  inner layer Eudragit alone (3 layers). Each 
layer was dried at room temperature for 24 h before adding the next layer. Thick Eudragit films (up to 1 
mm) were used to make spacers between laminated dried cell spots. Thermogravimetric analysis 
confirmed complete solvent removal to prevent toxicity. Prior to adding bacteria, films were sterilized 
by UV irradiation and handled aseptically. SL3261 cells were dried onto polymer films in 40 % w/v 
trehalose in a desiccator at 20 ºC for a minimum of 18 hours, with relative humidity remaining between 
4-6 % and temperature within ±1ºC monitored by USB datalogger (Omega, UK) and laminated 
together as previously described [17]. Prototype BR-PFL formulations were either tested directly in 
simulated intestinal fluids, or pre-incubated in simulated gastric fluid (SGF or BioSGF) (pH 1.8, 50 
mL) at 37 ºC for 2 hours in beakers with orbital shaking at 100 rpm, and compared to control PFL 
formulations. By visual inspection all formulations remained intact in gastric fluid, although samples 
were checked for live cell release. Formulations were transferred into 100 mL simulated intestinal fluid 
(SIF or BioSIF) at pH 7.2 and 37 ºC and live cell release was determined at 0, 1, 2 and 3h. 
Viable cell counting. Cell viability was evaluated using serial dilution of samples and agar plate 
colony counting. 5 µL samples of serial 3-fold dilutions were plated as spots onto LB agar. Colonies 
were counted after overnight incubation on spots with 5-30 colonies, and final viability calculated and 
presented as colony forming unit per mL (CFU/mL), per capsule for Vivotif tests (CFU/capsule), or per 
mg dry cell powder (CFU/mg) depending on the sample tested. To compare viablity post-drying vs 
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after GI testing, cell counts were expressed relative to the initial volume of the cell slurry before drying 
for PFL. 
Survival and cell release from encapsulated oral formulations. Complete formulations were tested 
in the gastro-small intestine model system which was anaerobic, pH controlled, water jacketed and 
magnetically stirred. In some experiments, where indicated, formulations and dried cell samples were 
testing in beakers under aerobic, pH pre-adjusted, with orbital shaking in an incubator. The 
formulations were placed first into SGF or BioSGF (50 mL, pH 1.8, stomach) and incubated (37 
o
C, 2 
h, orbital shaking at 100 rpm or magnetic stirred); a sample was taken at 2 h to determine live cell 
numbers. After, the formulation was transferred into SIF or BioSiF (pH 5.5, 100 mL, simulating 
duodenum) and incubated (37 ºC, 5 min, orbital shaking at 100 rpm or magnetically stirred), then into 
SIF or BioSIF (pH 6.5, 100 mL, simulating jejunum) and incubated (37 ºC, 25 min, orbital shaking at 
100 rpm or magnetically stirred), and finally, the formulations were placed into SIF or BioSIF (pH 7.2, 
100 mL, simulating Ileum) and incubated (37 ºC, 24 h, orbital shaking at 100 rpm or magnetic stirred). 
In the simulated stomach, duodenum and jejunum, a sample was taken just before removing the 
formulation to determine live cell numbers. In the virtual ileum the cells were counted at 1 h, 2.5 h and 
24 h. For each experiment, a replicate formulation was placed in LB broth or SIF+peptone (10 mL) and 
incubated at 37 ºC for 60 min, with shaking at 100 rpm, and cells counted to determine the total viable 
cell number per formulation for comparison.   
Protection of Vivotif formulation from bile and acid. Vivotif enteric-coated capsules (Crucell) were 
placed either in SGF or BioSGF (50 mL, pH 1.8, stomach) and incubated (37 ºC, 2 h, orbital shaking); 
a sample was taken at 2 h to determine live cell numbers. After 2h, the formulation was transferred into 
SIF or BioSiF (pH 7.2, 100 mL) and incubated (37 ºC, 3 h, orbital shaking at 100 rpm) with live cells 
counted after 3 h. Vivotif capsules were also aseptically opened and 10mg samples of dried cell powder 
placed into culture medium, SIF or BioSiF (pH 7.2, 100 mL) at 37 ºC, 3 h, with orbital shaking, with 
live cell numbers measured at 3h. To determine toxicity of the gastric stage, formulations were also 
placed directly into simulated intestinal fluids. To test the intrinsic bile sensitivity of Salmonella Typhi 
Ty21 after rehydration in culture medium, individually weighed samples of approximately 10 mg were 
placed in 50 mL tubes, and 10 mL of growth medium (LB broth) or SIF with or without 1% bile were 
added, followed by incubation at 37 °C and sampling live cell numbers at one hour. These were 
compared to Vivotif powder that was firstly rehydrated in 10 mL growth medium without bile for 0.5 
hours then 2 % bile added to provide a final concentration of 1% w/v. 
 
Statistical analysis 
All data were analysed by one-way ANOVA, using Tukey post-hoc test analysis when the overall P 
value of the experiment was below the value of significance (P<0.05). Analyses were performed using 
GraphPad Prism 5.0 (GraphPad Software, LaJolla, CA, USA). 
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Results and Discussion 
In vitro evaluation of viable cell release from oral live bacterial vaccine formulations using a 
complete GI model 
Initially we used a complete GI model (Fig. 1) to assess the release of live cells from two oral 
formulations of attenuated salmonella strains: firstly, the approved oral Typhoid Fever vaccine Vivotif 
containing dried Salmonella typhi strain Ty21a formulated in enteric coated capsules; and secondly an 
experimental enteric polymer film laminate (PFL) formulation, previously shown to completely protect 
dried cells of a live model vaccine (Salmonella Typhimurium strain SL3261) from acid when tested 
using simple SGF and SIF [25]. Surprisingly, when tested in the complete gastro-small intestine model 
with complete simulated gastric and intestinal fluids (bioSGF and bioSIF), the PFL released very few 
cells (~2x10
7 
CFU/mL), and no viable cells were recovered from the Vivotif capsules, (<detection limit 
of 10
5 
CFU/mL) (Fig. 2). After overnight culture, high bacterial cell concentrations of >10
10 
CFU/mL 
for Vivotif and >10
12 
CFU/mL for PFL were found (data not shown). The presence of peptone in the 
bioSIF medium allows cells to replicate within the model, therefore the high cell counts found after 
overnight incubation indicated that although too few viable cells were released to be detected at 300 
minutes, sufficient live cells were released to replicate overnight in the simulated intestinal fluids. This 
indicates that although inefficient at delivery, simulated GI transit was not totally sterilizing to these 
two formulations.  
The poor viable cell recovery from Vivotif capsules in the gut model is at first sight surprising given 
this formulation is a widely used and effective vaccine. However this convenient capsule formulation 
was shown in human trials to be significantly less immunogenic than when the same attenuated strain 
was administered in a carbonate buffer [8, 9], and multiple capsules must be taken on separate days for 
effective protective immunisation. Although cell recovery in the GI model was poor, live cells were 
recovered after overnight incubation, indicating that sufficient live cells had been released to replicate 
in situ. Furthermore, the number of live bacterial cells that must be delivered to the intestine to induce 
protective immunity in humans is unknown. Therefore it remains plausible that this simple and 
convenient capsule formulation is inefficient at delivering viable Ty21a bacteria in vivo – yet sufficient 
viable cells are delivered even with this suboptimal formulation to promote protective immunity in 
some recipients.  
The PFL formulations containing room temperature dried model live bacteria vaccine S. Typhimurium 
SL3261 were previously shown to effectively protect from gastric acid in simple SGF and SIF 
dissolution tests [17]. In contrast the significant drop in viable cell number when tested in complete 
simulated gastro-intestinal fluids (BioSGF and BioSIF) in the GI model (Fig. 2) suggested that this 
formulation, like the Vivotif enteric coated capsules, may also be not optimal for effective delivery of 
viable cells in vivo. 
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FIGURE 2. In vitro evaluation of live cell release from two oral live bacterial vaccine formulations in a complete 
gastro small intestine model. Vivotif enteric coated capsules containing dried S. Typhi Ty21a or a prototype oral polymer 
film laminate (PFL) formulation containing dried cells of the attenuated vaccine S. Typhimurium SL3261 were tested in the 
GI model by immersion in the dose holder in BioSGF for 2 hours followed by transfer into BioSIF at increasing pH, and 
viable cell release determined at the indicated timepoints. For comparison, the contents of aseptically opened Vivotif 
capsules or unformulated polymer films with identical doses of dried SL3261 cells were dispersed directly into culture 
medium to determine maximal dose of viable cells in each formulation. Viable cell counts are expressed as CFU per capsule 
for vivotif, or for PFL as CFU/ml normalised to the cell volume prior to drying, to allow comparison with cell density prior 
to drying and formulation. Each bar represents a single dose with the error bar indicating the standard deviation of 6 
replicate cell counts of each sample. Similar viable cell recovery and release kinetics were observed in 3 independent 
experiments. ND = not detected, with no colonies detected from undiluted samples, indicating viable cell recovery below a 
limit of detection of 10^5 CFU per dose. 
 
 
 
No loss of cells was observed when PFL were tested in a simple dissolution medium (SGF followed by 
SIF) in beakers, yet a similar major loss of cell viability was observed when PFL were tested in bioSGF 
followed by bioSIF in beakers to that observed in the semi-continuous complete gastro small intestinal 
model (Fig. 2, [17] and data not shown), confirming that the loss in viability could be attributed to the 
change in dissolution media composition rather than to differences in mixing conditions or vessel 
size/shape. This suggested that one or more components of the complex bioSIF is toxic to dried vaccine 
cells formulated in both enteric coated capsules and PFL formulations. 
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Impact of simulated fluid composition on cell survival in Vivotif capsules 
To fully understand the reasons for the poor live cell recovery from Vivotif capsules in the GI 
model, viable cell release from capsules was studied in shaken beakers and the effect of bile and gastric 
acid were evaluated separately. Surprisingly, when Vivotif capsules were placed into simple SIF or 
complex BioSIF either directly or after 2 h of acid challenge (SGF or BioSGF), the maximum viable 
cell recovery after 3h in shaken beakers was 7.6x10
6
 CFU/capsule, in SIF without pre-incubation in 
acid (Fig 3A). Capsules are loaded with at least 2x10
9
 CFU per capsule, so this represents surprisingly 
poor viable cell release. Indeed, when dry cell powder was aseptically removed from opened Vivotif 
capsules and dispersed directly in SIF or culture medium, the expected viable cell numbers were 
released (Fig. 3B), with 0.8 x10
9
 CFU/capsule and 2x10
9
 CFU/capsule released in SIF and culture 
medium respectively. This suggested that a major cause for low cell recovery from whole capsules is 
the inefficient release of capsule contents. Although capsules had visibly disintegrated after 3h at 
intestinal pH, a viscous gel was formed from the remains of the capsule shell that could potentially trap 
many of the bacteria limiting release and dispersal. In addition to inefficient release, significant 
reduction in viable cell release moving from culture medium to SIF and to BioSIF indicates that dried 
cells within the capsules are sensitive to the composition of the reconstitution buffer. When dried 
Vivotif powder was directly exposed to BioSIF, viability rapidly decreased giving a 1 log loss 
compared to powder dispersed into SIF, confirming that dried Ty21a cells in Vivotif are bile sensitive 
(Fig 3a). Similar loss in cell viability was observed when the Vivotif capsule content was tested in SIF 
with 1% bile addition, confirming that the major difference between SIF and BioSIF can be attributed 
to bile (rather than enzymes or differences in salt). The loss of viability can be attributed to transient 
bile sensitivity of dried cells  rather than any intrinsic sensitivity of Ty21a to bilesince after a 30 minute 
recovery period in culture medium, addition of 1% bile gave no reduction in cell viability (Fig. 3b), 
confirming that as expected S. typhi Ty21a cells are not intrinsically sensitive to bile. The high bile 
sensitivity of lyophilized Ty21a cells is consistent with previous studies of both thermostabilised dried 
Gram negative LBV and freeze-dried Gram positive probiotics [13, 14].  
When enteric coated Vivotif capsules were exposed to BioSIF either directly, or after 2 h in acid, 
viability rapidly dropped below the limit of detection (10
5
 CFU/mL), representing more than a 10
4 
fold 
loss. In contrast, when Vivotif capsule was placed directly into SIF, significant numbers of viable cells 
were recovered (~10
7
 CFU/mL). When the capsule was transferred into SIF following 2 h in SGF, cell 
survival was reduced with ~1 log loss in viability attributed to immersion in acid, demonstrating that 
although the capsule enteric coating provides significant protection from acid and prevents release at 
gastric pH, some acid penetration occurred, suggesting the enteric coating on this formulation may not 
provide complete gastric acid resistance.  
In summary, the failure to recover viable Ty21a cells from Vivotif capsules in the complete GI 
model (Fig 2) can be attributed to a combination of incomplete release of live cell contents (Fig. 3a vs 
b), incomplete protection from gastric acid (Fig 3a), combined with sensitivity of the dried cells to bile 
after release in BioSIF (Fig. 3a & b). 
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FIGURE 3. Characterizing live cell release from Vivotif capsules and bile sensitivity of dried Ty21a cells. A Release 
of viable S. Typhi Ty21a cells from enteric coated Vivotif capsules was evaluated after 3h incubation in 100mL of simple 
(SIF) or complete (BioSIF) simulated intestinal fluid compositions in beakers with orbital shaking, either directly added or 
following 2h incubation in the indicated simulated gastric fluid. Viable cell counts were expressed as CFU/capsule. B The 
sensitivity of dried cells from Vivotif capsules was tested at 1h after dispersal of samples of approximately 10mg powder 
into SIF or BioSIF and compared to powder dispersed in culture medium. To demonstrate that the observed sensitivity to 
bile of dried Ty21a cells was reversible, 10mg samples were either dispersed in culture medium for 30 minutes followed by 
addition of bile dissolved in SIF to give a final concentration of 1% (bile added t=30), or directly dispersed in a mixture of 
culture medium and SIF with bile at 1% (bile added t=0min), followed by evaluation of viable cell counts at 1h. Viable cell 
numbers were calculated and can be evaluated on two axes: either as CFU/capsule (left axis, for comparison with part A) or 
as CFU/mg dried cell powder (right axis). Capsules contained 180mg dried cell powder. Data are representative of at least 3 
repeat experiments. 
 
 
Developing bile resistant PFL incorporating bile adsorbent resin 
The surprisingly poor delivery of viable bacteria from enteric coated capsules suggests that 
improved formulations for oral delivery of LBV are required. Previous studies using tablets and 
capsules showed that transiently bile sensitive dried cells can be protected with bile adsorbing resins 
[12, 24]. Having previously established that drying live bacteria directly onto enteric polymer films and 
formulation into PFL provided effective protection from acid and controllable release kinetics [17], we 
explored here whether bile adsorbing resins can likewise be incorporated into this simple novel 
formulation to protect dried cells from bile. Four pilot formulations were produced and evaluated in 
simple release studies comprising incubation for 2h in SGF or BioSGF in beakers, then transfer into 
beakers of either SIF or BioSIF at pH 6.8, with sampling after 2 h in acid and at 1h and 3h at intestinal 
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pH. The pilot formulations included: an unmodified control PFL made from laminated enteric polymer 
alone; formulation BR-PFL B with a single layer of Eudragit cast from polymer solution mixed with 
bile adsorbing resin; formulation BR-PFL C comprising two polymer layers, with the external layer 
cast from enteric polymer alone and an internal layer cast from enteric polymer mixed with bile 
adsorbing resin; and BR-PFL D with three polymer layers, with a central layer cast from enteric 
polymer mixed with bile adsorbing resin surrounded with (Fig. 4 top). 
The first and simplest prototype formulation BR-PFL B showed high cell losses after immersion in 
acid, likely caused by acid penetration through the enteric film during incubation in SGF/BioSGF 
caused by porous particles of bile adsorbing resin embedded in the film (Fig. 4). This formulation was 
not selected for further tests, and subsequent BR-PFL prototypes were designed to overcome the 
porosity of films cast from enteric polymer mixed with bile adsorbing resins.  
BR-PFL C and BR-PFL D both provided effective protection from acid (Fig. 4). Both had an outer 
polymer film layer cast from Eudragit alone that completely protected the PFL from acid, and the bile 
adsorbing resin was incorporated into an inner layer. BR-PFL D had a third additional thin inner layer 
of Eudragit film onto which the cells were dried. Like PFL, excellent cell recovery of >10
9
 CFU/ml 
after 2h in SGF and 3 h in SIF indicated effective acid protection, with identical cell recovery to 
replicate samples directly dispersed in SIF without lamination indicating no loss in viability during 2 h 
in SGF (Fig. 4b). When tested in BioSIF and BioSGF, far higher viable cell numbers were recovered 
from BR-PFL C and BR-PFL D compared to the PFL without bile adsorbent resin. The PFL alone 
provided some protection from bile containing Bio-SIF, with 1.5 log higher cell recovery compared to 
that observed in non-laminated dried cells exposed to 1 % bile, suggesting that cast films of Eudragit 
can provide protection from bile to dried cells, as observed previously with HPMC capsule shells [24]. 
However, the best recovery, with > 2 log higher recovery than direct exposure to 1% bile, was 
observed with BR-PFL C and BR-PFL D (Fig. 4), demonstrating that enteric polymer films 
incorporating bile adsorbing resins can protect dried LBV cells from both bile and acid.  
Although different release kinetics were observed depending on the lamination method (and 
simulated intestinal fluid composition), all formulations released maximal viable cells by 3 h in BioSIF 
following 2 h in BioSGF. BR-PFL D had slower release kinetics in SIF, likely due to the increased 
thickness of the three layered system which takes longer to swell, dissolve and fully release contents at 
elevated pH. All other formulations had more rapid release kinetics in SIF – with complete release by 1 
h – than in BioSIF where 3h was required for total release, indicating that fluid composition not only 
affects LBV viability but also release kinetics. This may be related to buffer concentration, with SIF 
having a 30 % higher buffer concentration than BioSIF, consistent with prior study demonstrating that 
release from enteric coated dosage forms at small intestinal pHs is buffer concentration dependent [25]. 
In conclusion, using laminated multiple layer films cast from pH responsive enteric polymer plus 
bile adsorbing resins we produced a simple oral formulation that protects dried LBV from both acid 
and bile and allows release of high numbers of viable cells with release kinetics controlled by film 
thickness. 
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FIGURE 4. Developing bile resistant polymer film laminate formulations. S. Typhimurium SL3261 cells were dried 
onto cast polymer films and made into either PFL (A) or prototype bile resistant PFL (BR-PFL) with the bile adsorbing 
resin cholestyramine incorporated into different polymer layers as illustrated in the top panel (formulations B, C, and D). 
The acid and bile resistance of the novel PFL formulations was tested in simulated gastrointestinal fluids by immersion in 
acid for 2 hours followed by transfer into either simple SIF or complete BioSIF for 3 hours. Cell viability was tested after 1h 
and 3 h in the intestinal fluid, and cell counts expressed relative to the volume initially dried into each formulation (i.e. 
relative CFU/ml). Each bar represents a single formulation with error bars indicating standard deviation of 6 replicate cell 
counts. Similar viable LBC recovery was observed in 3 different experiments comparing different BR-PFL formulations. 
ND = not detected, with no colonies detected from undiluted samples, indicating viable cell recovery below a limit of 
detection of 10^5 CFU per dose. 
 
BR-PFL oral formulation for controlled delivery of vaccine in in vitro upper GI model  
Having established in pilot tests that version D of the BR-PFL provided effective acid and bile 
resistance in simple shaken beaker studies, this enteric oral formulation was then tested in the complete 
multi-stage in vitro GI model (Fig. 1) to evaluate live cell delivery of LBV during simulated 
gastrointestinal transit. BR-PFL containing dried S. typhimurium SL3261 were inserted in customized 
holders, and placed into vessel 1- stomach for 2 h, then transferred to vessel 2 – duodenum for 5 
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minutes, then transferred to vessel 3 - jejunum for 25 min and finally transferred to vessel 4 – ileum for 
2.5 h, with a complete transit time of 5 h. Samples to determine viability were taken after 2h in the 
gastric stage and the small intestine stages were sampled at 2 h 5 min, 2.5h, 3.5 h and 5 h. As expected 
from the beaker studies, when BR-PFL D was incubated in the initial BioSGF stage, the formulation 
remained intact and no cells were recovered. After transfer to the intestinal stages, high numbers of 
viable cells were released (Fig. 5). Viable cell release plateaued after only 60 minutes at pH 7.2, 
corresponding to a gastrointestinal transit of 3.5 h. When compared to replicate samples of cells dried 
onto enteric polymer films dispersed directly in SIF after drying, less than 0.5 log loss in viability was 
observed, suggesting the BR-PFL is effective at blocking both gastric acid and intestinal bile toxicity, 
and therefore highly suited for efficient oral delivery of therapeutic live bacterial cells. 
 
FIGURE 5. In vitro evaluation of prototype Bile Resistant Polymer Film Laminate (BR-PFL) in the gastro small 
intestine model demonstrating effective protection and release of dried live cells in intestinal conditions. S. 
Typhimurium SL3261 cells were dried onto triple layered films of enteric polymer and bile adsorbant resin, and laminated 
into BR-PFL formulations. The viable cell count prior to drying and post-drying viability of non-laminated samples were 
measured (left). Duplicate BS-PFL formulations were placed into a dose holder and sequentially immersed in the four 
stages, starting with BioSGF for 2 hours followed by transfer into BioSIF at increasing pH, and viable cell release sampled 
at the indicated timepoints. Viable cell counts are expressed normalised to the initial volume of cell slurry prior to drying to 
allow simple comparison in each stage. The prototype BR-PFL contained 10μL of cells prior to drying, thus each dose 
released 4x10
7
 CFU. Each bar represents a single BS-PFL formulation with the error bar indicating the standard deviation of 
6 replicate cell counts of each sample. Similar viable cell recovery and release kinetics were observed in 3 independent 
experiments. ND = not detected, with no colonies detected from undiluted samples, indicating viable cell recovery below a 
limit of detection of 10^5 CFU per dose. 
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Conclusion  
This study illustrates the importance of using in vitro models that closely mimic human GI conditions 
for studying the formulation and release of complex biopharmaceuticals such as live bacterial cells. 
Significant differences in cell viability and kinetics of release were observed when experimental 
formulations were tested in a complex gastro small intestine model compared to conventional 
dissolution apparatus, reinforcing the importance of matching fluid composition of GI models to in vivo 
conditions when testing formulations. Both oral vaccine formulations tested – both conventional 
Vivotif capsules and the novel PFL – showed high losses in viable cells numbers during simulated 
gastrointestinal transit even though both contained high cell numbers of dried cells that could be 
released in simple dissolution media such as USP SIF. Using a gut model system it was possible to 
develop an improved PFL oral formulation for live vaccine bacterial delivery to the distal small 
intestine, by incorporating additional excipients to protect dried live cells from bile. The optimized BR-
PFL oral formulation gave protection from both acid and bile and allows controlled enteric delivery of 
a dose of 4x10
7
 CFU of a model attenuated vaccine, with higher doses possible by increasing the 
quantity of dried cells in the formulation. Although in vitro modelling remains the best way to 
understand and control both the effect of food and nutritional supplements on gut health, but also the 
fate of orally administered drugs in the GI tract, further studies of novel live bacterial vaccines 
formulations such as BR-PFL are needed to determine in vivo cell delivery performance and ultimate 
immunogenicity and efficacy. 
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